Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

 
Press Releases
Date Title and Summary View
Jun 6, 2005 CHARLESTOWN, MA June 6, 2005 - ZIOPHARM, Inc. announced today that it had completed its Series A Convertible Preferred Stock offering. Paramount BioCapital, Inc. served as the lead placement agent and gross proceeds were approximately $18.1 million. The net proceeds from the Offering will be used for research and development, licensing fees a...
PDF
May 25, 2005 CHARLESTOWN, MA May 25, 2005 - ZIOPHARM, Inc. announced today that it has initiated its second phase I study to assess safety and dosing of ZIO-101, the Company's proprietary small molecule organic arsenic. This trial is being conducted in up to 40 patients with diverse solid tumors and complements the recently initiated phase I study in pati...
PDF
May 19, 2005 CHARLESTOWN, MA May 19, 2005 - ZIOPHARM, Inc. announced dosing of the first patient in its phase I study of the safety and dosing of ZIO-101, the Company's proprietary small molecule organic arsenic. The study, in up to 40 patients with diverse blood and bone marrow cancers, started on schedule just nine months after the Company licensed ZIO-...
PDF
Apr 19, 2005 NEW HAVEN, CT April 19, 2005 - ZIOPHARM, Inc. announced today Dr. Lee Roy Morgan presented the preclinical pharmacology and toxicology data for ZIO-201 (L-IPM , or lysine-isophosphoramide mustard) at the American Association for Cancer Research (AACR) meeting in Anaheim, California. ZIO-201 is the Company's proprietary alkylating drug and the...
PDF
Apr 5, 2005 NEW HAVEN, CT April 5, 2005 - ZIOPHARM, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug Application (IND) for the clinical development of its proprietary organic arsenic compound, ZIO-101. The Company plans to initiate a dose-ranging Phase I trial of ZIO-101 in patients with hema...
PDF
Jan 7, 2005 NEW HAVEN, CT JAN. 7 - ZIOPHARM, Inc. announced today that it has entered into a two-year research Collaboration Agreement with the Southern Research Institute of Birmingham, Alabama to develop a series of IPM (isophosphoramide mustard) analogs. In conjunction with the research agreement, ZIOPHARM also signed a two-year Option Agreement to en...
PDF
Dec 6, 2004 SAN DIEGO, DEC. 6 -- ZIOPHARM, Inc. today announced that Dr. Xiaodong Cheng, MD from The University of Texas M.D. Anderson Cancer Center presented preclinical data on ZIO-102, the second of the Company's organic arsenic products. Data were presented at the 46th Annual Meeting of the American Society of Hematology (ASH), December 3-8, in San Di...
PDF
Nov 10, 2004 NEW HAVEN, CT NOVEMBER 10 - ZIOPHARM, Inc. announced it has secured an exclusive worldwide license to a novel and proprietary form of isophosphoramide mustard (IPM) from DEKK-TEC, Inc. of New Orleans. The new compound, ZIO-201, is currently in a Phase I clinical trial at the Karmanos Cancer Institute at Wayne State University in Michig...
PDF
Oct 26, 2004 NEW HAVEN, CT. OCT. 26 - ZIOPHARM, Inc. announced it received a Notice of Allowance from the US Patent and Trademark Office for US Patent Application No. 10/337969 titled "S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(simethylarsino) glutathione as treatments for cancer." The patent application claims both ...
PDF
Sep 20, 2004 NEW HAVEN, CT SEPT 20 - ZIOPHARM today announced that Dr. Srdan Verstovsek, MD, and his colleagues at The University of Texas M. D. Anderson Cancer Center reported mouse study data on the company's lead compound, ZIO-101, showing they were able to increase the arsenic dose 30-to-50-fold over that of inorganic arsenic without experiencing any se...
PDF
Page: FirstPrevious ...
40
NextLast